<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0406257546
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1991
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZESTRIL 20MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LISINOPRIL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        44.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Rovi Pharma Industrial Service" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Rovi Pharma Industrial Service
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Atnahs Pharma UK Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zestril contains a medicine called lisinopril. This belongs to a group of medicines called ACE inhibitors.<br />Zestril can be used for the following conditions:</p><ul><li>&nbsp;To treat high blood pressure (hypertension).</li><li>&nbsp;To treat heart failure.</li><li>&nbsp;If you have recently had a heart attack (myocardial infarction).</li><li>To treat kidney problems caused by Type II diabetes in people with high blood pressure.</li></ul><p>Zestril works by making your blood vessels widen. This helps to lower your blood pressure. It also makes it easier for your heart to pump blood to all parts of your body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zestril:</strong></p><ul><li>&nbsp;if you are allergic to lisinopril or any of the other ingredients of this medicine (listed in section 6).</li><li>&nbsp;if you have ever had an allergic reaction to another ACE inhibitor medicine. The allergic reaction may have caused itching, hives, sudden fall in blood pressure,&nbsp; swelling of the hands, feet, ankles, face, lips, tongue or throat. It may also have made it difficult to swallow or breathe (angioedema).</li><li>&nbsp;if a member of your family has had severe allergic reactions (angioedema) to an ACE inhibitor or you have had severe allergic reactions (angioedema) without a known cause.</li><li>if you are more than 3 months pregnant. (It is also better to avoid Zestril in early pregnancy - see pregnancy section).</li><li>&nbsp;If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</li></ul><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Zestril.<br />If you develop a dry cough which is persistent for a long time after starting treatment with Zestril, talk to your doctor.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Zestril.</p><ul><li>&nbsp;if you have a narrowing (stenosis) of the aorta (an artery in your heart) or a narrowing of the heart valves (mitral valves).</li><li>If you are taking any of the following medicines used to treat high blood pressure:<br />- an angiotensin II receptor blocker (ARBs) (also known as sartans &ndash; for example<br />valsartan, telmisartan, irbesartan), in particular if you have diabetes related kidney<br />problems<br />- Aliskiren<br />- If you are taking medicines called mTOR inhibitors (for example temsirolimus,everolimus, sirolimus) or medicines containing NEP inhibitors (for example racecadotril) as they may increase the risk of angioedema. Signs of angioedema include swelling of the face, lips, tongue and/or throat with difficulty in swallowing<br />- or breathing.<br />- Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.<br />- See also information under the heading &ldquo;Do not take Zestril.&rdquo;</li><li>&nbsp;if you have a narrowing (stenosis) of the kidney artery.</li><li>&nbsp;if you have an increase in the thickness of the heart muscle (known as hypertrophic cardiomyopathy).</li><li>&nbsp;if you have problems with your blood vessels (collagen vascular disease).</li><li>&nbsp;if you have low blood pressure. You may notice this as feeling dizzy or light-headed, especially when standing up.</li><li>&nbsp;if you have kidney problems or you are having kidney dialysis.</li><li>&nbsp;if you have liver problems.</li><li>&nbsp;if you have diabetes.</li><li>&nbsp;if you have recently had diarrhoea or vomiting (being sick).</li><li>&nbsp;if your doctor has told you to control the amount of salt in your diet.</li><li>&nbsp;if you have high levels of cholesterol and you are having a treatment called &lsquo;LDL apheresis&rsquo;.</li><li>&nbsp;You must tell your doctor if you think you are (or might become) pregnant. Zestril is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</li><li>&nbsp;if you are of black origin as Zestril may be less effective. You may also more readily get the side effect &lsquo;angioedema&rsquo; (a severe allergic reaction).</li></ul><p>If you are not sure if any of these apply to you, talk to your doctor or pharmacist before taking Zestril.<br /><strong>Treatment for allergies such as insect stings</strong><br />Tell your doctor if you are having or are going to have treatment to lower the effects of an allergy such as insect stings (desensitisation treatment). If you take Zestril while you are having this treatment, it may cause a severe allergic reaction.</p><p><strong>Operations</strong><br />If you are going to have an operation (including dental surgery) tell your doctor or dentist that you are taking Zestril. This is because you can get low blood pressure&nbsp;(hypotension) if you are given certain local or general anaesthetics while you are taking Zestril.</p><p><strong>Children and adolescents</strong><br />Zestril has been studied in children. For more information, talk to your doctor. Zestril is not recommended in children under 6 years of age or in any child with severe kidney problems.<br /><strong>Taking other medicine</strong><br />Tell your doctor if you are taking, or have recently taken, or might take any other medicines. This is because Zestril can affect the way some medicines work and some medicines can have an effect on Zestril.<br />In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><ul><li>&nbsp;Other medicines for treatment of high blood pressure (antihypertensives) including an angiotensin II receptor blocker (ARB)<br />or aliskiren, (see also information under the headings &ldquo;Do not take<br />Zestril&rdquo; and &ldquo;Take special care with Zestril&rdquo;).</li><li>Aliskiren containing medicines (for treatment of high blood pressure).</li><li>&nbsp;Water tablets (diuretic medicines).</li><li>&nbsp;Medicines to break up blood clots (usually given in hospital).</li><li>&nbsp;Beta-blocker medicines, such as atenolol and propranolol.</li><li>&nbsp;Nitrate medicines (for heart problems).</li><li>&nbsp;Non-steroidal anti-inflammatory drugs (NSAIDs) used to treat pain and arthritis.</li><li>&nbsp;Aspirin (Acetylsalicylic acid), if you are taking more than 3 grams each day.</li><li>&nbsp;Medicines for depression and for mental problems, including lithium.</li><li>&nbsp;Potassium supplements,&nbsp;substitutes&nbsp;containing potassium or other drugs which can increase potassium in your body.&nbsp;</li><li>&nbsp;Insulin or medicines that you take by mouth for diabetes.</li><li>Medicines to treat cancer (such as everolimus) and medicines given to prevent the body from rejecting a transplanted organ, e.g. kidney or liver (such as temsirolimus,sirolimus).</li><li>Racecadotril used to treat diarrhoea.</li><li>Tissue plasminogen activator (TPA) that is used to dissolve blood clots that have formed in blood vessels.</li><li>&nbsp;Medicines used to treat asthma.</li><li>&nbsp;Medicines to treat nose or sinus congestion or other cold remedies (including those you can buy in the pharmacy).</li><li>&nbsp;Medicines to suppress the body&rsquo;s immune response (immunosuppressants).</li><li>&nbsp;Allopurinol (for gout).</li><li>&nbsp;Procainamide (for heart beat problems).</li><li>&nbsp;Medicines that contain gold, such as sodium aurothiomalate, which may be given to you as an injection.</li></ul><p><strong>Pregnancy and breast-feeding</strong><br />Pregnancy:<br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Zestril before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Zestril. Zestril is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.<br />Breast-feeding:<br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Zestril is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.<br /><strong>Driving and using machines</strong></p><ul><li>&nbsp;Some people feel dizzy or tired when taking this medicine. If this happens to you, do not drive or use any tools or machines.</li><li>&nbsp;You must wait to see how your medicine affects you before trying these activities.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.<br />Once you have started taking Zestril your doctor may take blood tests. Your doctor may then adjust your dose so you take the right amount of medicine for you.</p><p><strong>Taking your medicine</strong></p><ul><li>&nbsp;Swallow the tablet with a drink of water.</li><li>&nbsp;Try to take your tablets at the same time each day. It does not matter if you take Zestril before or after food.</li><li>&nbsp;Keep taking Zestril for as long as your doctor tells you to, it is a long term treatment. It is important to keep taking Zestril every day.</li></ul><p><strong>Taking your first dose</strong></p><ul><li>Take special care when you have your first dose of Zestril or if your dose is increased. It may cause a greater fall in blood pressure than later doses.</li><li>&nbsp;This may make you feel dizzy or light-headed. If this happens, it may help to lie down. If you are concerned, please talk to your doctor as soon as possible.</li></ul><p><strong>Adults</strong><br />Your dose depends on your medical condition and whether you are taking any other medicines. Your doctor will tell you how many tablets to take each day. Check with your doctor or pharmacist if you are unsure.<br /><strong>For high blood pressure</strong></p><ul><li>&nbsp;The recommended starting dose is 10 mg once a day.</li><li>&nbsp;The usual long-term dose is 20 mg once a day.</li></ul><p><strong>For heart failure</strong></p><ul><li>&nbsp;The long-term dose is 5 to 35 mg once a day.</li></ul><p><strong>After a heart attack</strong></p><ul><li>&nbsp;The recommended starting dose is 5 mg within 24 hours of your attack and 5 mg one day later.</li><li>&nbsp;The usual long-term dose is 10 mg once a day.</li></ul><p><strong>For kidney problems caused by diabetes</strong></p><ul><li>&nbsp;The recommended dose is either 10 mg or 20 mg once a day.</li></ul><p>If you are elderly, have kidney problems or are taking diuretic medicines your doctor may give you a lower dose than the usual dose.<br /><strong>Use in children and adolescents (6 to 16 years old) with high blood pressure</strong></p><ul><li>&nbsp;Zestril is not recommended for children under 6 years or in any children with severe kidney problems.</li><li>&nbsp;The doctor will work out the correct dose for your child. The dose depends on the child&rsquo;s body weight.</li><li>&nbsp;For children who weigh more than 50 kg, the recommended starting dose is 5 mg once a day.</li></ul><p><strong>If you take more Zestril than you should</strong><br />If you take more Zestril than prescribed by your doctor, talk to a doctor or go to a hospital immediately. The following effects are most likely to happen: Dizziness, palpitations.<br /><strong>If you forget to take Zestril</strong></p><ul><li>&nbsp;If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose.</li><li>&nbsp;Do not take a double dose to make up for a forgotten dose.</li></ul><p><strong>If you stop taking Zestril</strong><br />Do not stop taking your tablets, even if you are feeling well, unless your doctor tells you to.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you experience any of the following reactions, stop taking Zestril and see your doctor immediately:</p><ul><li>&nbsp;Severe allergic reactions (rare, affects 1 to 10 users in 10,000). The signs may include sudden onset of:</li></ul><p>- Swelling of your face, lips, tongue or throat. This may make it difficult to swallow.<br />- Severe or sudden swelling of your hands, feet and ankles.<br />- Difficulty breathing.<br />- Severe itching of the skin (with raised lumps).</p><ul><li>&nbsp;Severe skin disorders, like a sudden, unexpected rash or burning, red or peeling skin (very rare, affects less than 1 user in 10,000).</li><li>&nbsp;An infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems (very rare, affects less than 1 user in 10,000).</li></ul><p><strong>Other possible side effects:</strong><br />Common (affects 1 to 10 users in 100)</p><ul><li>Headache.</li><li>&nbsp;Feeling dizzy or light-headed, especially if you stand up quickly.</li><li>&nbsp;Diarrhoea.</li><li>&nbsp;A dry cough that does not go away.</li><li>&nbsp;Being sick (vomiting).</li><li>Kidney problems (shown in a blood test).</li></ul><p><strong>Uncommon (affects 1 to 10 users in 1,000)</strong></p><ul><li>&nbsp;Mood changes.</li><li>&nbsp;Change of colour in your fingers or toes (pale blue followed by redness) or numbness or tingling in your fingers or toes.</li><li>&nbsp;Changes in the way things taste.</li><li>&nbsp;Feeling sleepy.</li><li>Spinning feeling (vertigo).</li><li>Having difficulty sleeping.</li><li>&nbsp;Stroke.</li><li>&nbsp;Fast heart beat.</li><li>&nbsp;Runny nose.</li><li>&nbsp;Feeling sick (nausea).</li><li>&nbsp;Stomach pain or indigestion.</li><li>&nbsp;Skin rash or itching.</li><li>&nbsp;Being unable to get an erection (impotence).</li><li>&nbsp;Feeling tired or feeling weak (loss of strength).</li><li>A very big drop in blood pressure may happen in people with the following conditions: coronary heart disease; narrowing of the aorta (a heart artery), kidney artery or heart valves; an increase in the thickness of the heart muscle. If this happens to you, you may feel dizzy or light-headed, especially if you stand up quickly.</li><li>&nbsp;Changes in blood tests that show how well your liver and kidneys are working.</li><li>&nbsp;Heart attack.</li><li>&nbsp;Seen and/or heard hallucinations.</li></ul><p><strong>Rare (affects 1 to 10 users in 10,000)</strong></p><ul><li>Feeling confused.</li><li>&nbsp;A lumpy rash (hives).</li><li>&nbsp;Dry mouth.</li><li>Hair loss.</li><li>&nbsp;Psoriasis (a skin problem).</li><li>Changes in the way things smell.</li><li>Development of breasts in men.</li><li>Changes to some of the cells or other parts of your blood. Your doctor may take blood samples from time to time to check whether Zestril has had any effect on your blood. The signs may include feeling tired, pale skin, a sore throat, high temperature (fever), joint and muscle pains, swelling of the joints or glands, or sensitivity to sunlight.</li><li>&nbsp;Low levels of sodium in your blood (the symptoms may be tiredness, headache, nausea, vomiting).</li><li>Sudden renal failure.</li></ul><p><strong>Very rare (affect less than 1 user in 10,000)</strong></p><ul><li>&nbsp;Sinusitis (a feeling of pain and fullness behind your cheeks and eyes).</li><li>&nbsp;Wheezing.</li><li>&nbsp;Low levels of sugar in your blood (hypoglycaemia). The signs may include feeling hungry or weak, sweating and a fast heart beat.</li><li>&nbsp;Inflammation of the lungs. The signs include cough, feeling short of breath and high temperature (fever).</li><li>&nbsp;Yellowing of the skin or the whites of the eyes (jaundice).</li><li>&nbsp;Inflammation of the liver. This can cause loss of appetite, yellowing of the skin and eyes, and dark coloured urine.</li><li>&nbsp;Inflammation of the pancreas. This causes moderate to severe pain in the stomach.</li><li>&nbsp;Severe skin disorders. The symptoms include redness, blistering and peeling.</li><li>&nbsp;Sweating.</li><li>&nbsp;Passing less water (urine) than normal or passing no water.</li><li>&nbsp;Liver failure.</li><li>&nbsp;Lumps.</li><li>&nbsp;Inflamed gut.</li></ul><p><strong>Not known (frequency cannot be estimated from available data)</strong></p><ul><li>&nbsp;Symptoms of depression.</li><li>&nbsp;Fainting.</li><li>Serious allergic reaction</li></ul><p>Side effects in children appear to be comparable to those seen in adults.<br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly&nbsp;(see details below). By reporting side effects you can help provide more information on the safety of this medicine. [To be completed nationally]</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep this medicine out of the sight and reach of children.</li><li>5 mg, 10 mg 20 mg and 30 mg tablets: Do not store above 30&deg;C.</li><li>&nbsp;Do not use this medicine after the expiry date (EXP) which is stated on the blister strip and the carton. The expiry date refers to the last day of that month.</li><li>&nbsp;Do not throw away any medicines via waste-water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is lisinopril (as dihydrate).</li><li>The other ingredients are mannitol, calcium hydrogen phosphate dihydrate, maize starch, pregelatinised starch and magnesium stearate. In addition, the pink and brownish-red</li></ul><p>tablets contain red iron oxide (E172).<br />Zestril is supplied in 3 strengths containing 5 mg, 10 mg or 20 mg of lisinopril (as dihydrate).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zestril 5 mg Tablets: round, pink, uncoated, biconvex tablet with “♥ 5” on one side and bisected on the other side. Diameter 6 mm.
The tablet can be divided into equal doses.
Zestril 10 mg Tablets: round, pink, uncoated, biconvex tablet with “♥ 10” on one side and plain on the other side. Diameter 8 mm.
Zestril 20 mg Tablets: round, brownish-red, uncoated, biconvex tablet with “♥ 20” on one side and plain on the other side. Diameter 8 mm.
Zestril tablets are available in aluminium foil blister packs of 28 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorisations for Zestril are held by AstraZeneca UK Ltd, 600 Capability Green, Luton, LU1 3LU, UK.<br />Zestril is manufactured by AstraZeneca UK Limited, Silk Road Business Park, Macclesfield, Cheshire SK10 2NA, UK.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>يحتوي زستريل على مادة تسمى ليسينوبريل. تنتمي هذه المادة إلى مجموعة من الأدوية</p><p>يُطلق عليها الأدوية مثبطات ACE .</p><p>يمكن استخدام زستريل في الحالات التالية :</p><ul><li>&nbsp;لعلاج ضغط الدم العالي (فرط ضغط الدم).</li><li>&nbsp;لعلاج فشل القلب.</li><li>&nbsp;إذا حدثت لك مؤخرًا نوبة قلبية (احتشاء عضلة القلب).</li><li>&nbsp;لعلاج مشكلات الكلى الناجمة عن مرض السكري من النوع الثاني لدى الأشخاص الذين يعانون من ارتفاع ضغط الدم.</li></ul><p>يعمل زستريل عبر توسيع الأوعية الدموية. يساعد ذلك على خفض ضغط الدم. يسهّل كذلك</p><p>عملية ضخ القلب للدم إلى جميع أجزاء الجسم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p><strong>لا تتناول عقار زستريل :</strong></p><ul><li>&nbsp;إذا كانت لديك حساسية تجاه ليسينوبريل أو أي مادة أخرى من مكونات هذا الدواء (مذكورة في القسم 6)</li><li>&nbsp;إذا كنت قد عانيت من تفاعل تحسسي تجاه دواء مثبط ACE آخر. قد يتسبب التفاعل التحسسي&nbsp;الحكة والشرى وانخفاض مفاجئ في ضغط الدم&nbsp;وفي تورم اليدين أو القدمين أو الكاحلين أو الوجه أو الشفتين أو اللسان أو الحلق. قد يؤدي أيضًا إلى صعوبة في البلع أو التنفس (الوذمة الوعائية).</li><li>&nbsp;إذا عانى أحد أفراد أسرتك من تفاعلات تحسسية حادة (وذمة وعائية) تجاه أحد مثبطات ACE أو تكون أنت عانيت من تفاعلات تحسسية حادة (وذمة وعائية) بدون أي سبب معروف.</li><li>&nbsp;إذا كنتِ حام لا لأكثر من 3 أشهر. (من الأفضل أيضًا تجنب استعمال زستريل في الفترة الأولى من الحمل - انظري قسم الحمل).</li><li>&nbsp;إذا كنت تأخذ أدوية ضغط الدم التي تحتوي على اليسكيرين وكان لديك مرض السكري.</li><li>&nbsp;إذا كنت تأخذ أدوية ضغط الدم التي تحتوي على اليسكيرين وكان لديك مشاكل في الكلى.</li></ul><p>إذا لم تكن متأكدًا إذا كان أيا من هذه ينطبق عليك، فتحدّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول زستريل.<br />إذا تطورت لديك حالة من السعال الجاف واستمرت وقتًا طوي لا بعد بدء العلاج بزستريل، فتحدث إلى الطبيب.</p><p><strong>التحذيرات والتدابير الوقائية:</strong><br />تحدث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار زستريل :</p><ul><li dir="rtl">&nbsp;إذا كنت تعاني من ضيق (تضيّق) في الأبهر (شريان في القلب) أو ضيق في صمامات القلب (الصمامات الميترالية).</li><li dir="rtl">إذا كنت تتناول أي من الأدوية التالية المستخدمة في علاج ارتفاع ضغط الدم:<br />-&nbsp;حاصرات مستقبلات الأنجيوتنسين 2 (ARBs)&nbsp;&nbsp;(تُعرف أيضًا باسم السارتان - على سبيل المثال فالسارتان، تيلميسارتان، إربيسارتان) ، خاصةً إذا كنت تعاني من مشاكل في الكلى مرتبطة بمرض السكري<br />- أليسكرين<br />- إذا كنت تتناول أدوية تُسمى مثبطات mTRO (على سبيل المثال تمسيروليموس،&nbsp;إيفيروليموس، سيروليموس)&nbsp;أو أدوية تحتوي على مثبطات NEP (على سبيل المثال&nbsp;راسيكادوتريل)&nbsp;لأنها قد تزيد من خطر الإصابة بالوذمة الوعائية. تشمل علامات الوذمة&nbsp;الوعائية تورّم الوجه والشفتين واللسان و/أو الحلق مع صعوبة في البلع</li></ul><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; -&nbsp; أو التنفس&nbsp;</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - قد يقوم طبيبك بفحص وظائف الكلى وضغط الدم وكمية الشوارد (مثل البوتاسيوم) في&nbsp;دمك على فترات منتظمة.</p><p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;-&nbsp;راجع أيضًا المعلومات الواردة تحت العنوان &quot;لا تتناول زيستريل&quot;.</p><ul><li dir="rtl">&nbsp;إذا كنت تعاني من ضيق (تضيّق) في الشريان الكلوي.</li><li dir="rtl">&nbsp;إذا كنت تعاني من زيادة في كثافة عضلة القلب (والتي تعرف باسم اعتلال عضلة القلب الضخامي).</li><li dir="rtl">&nbsp;إذا كنت تعاني من مشكلات في الأوعية الدموية (مرض كولاجيني وعائي).</li><li dir="rtl">&nbsp;إذا كنت تعاني من انخفاض في ضغط الدم. قد تلاحظ هذا كشعور بالدوار أو الدوخة، خصوصًا عند الوقوف.</li><li dir="rtl">&nbsp;إذا كنت تعاني من مشكلات في الكلى أو تقوم بالغسيل الكلوي.</li><li dir="rtl">&nbsp;إذا كنت تعاني من مشكلات في الكبد.</li><li dir="rtl">&nbsp;إذا كنت مصابًا بمرض السكري.</li><li dir="rtl">&nbsp;إذا كنت تعاني مؤخرًا من الإسهال أو التقيؤ (الإصابة بالمرض).</li><li dir="rtl">&nbsp;إذا طلب منك طبيبك التحكم بكمية الملح في نظامك الغذائي.</li><li dir="rtl">&nbsp;إذا كنت تعاني من مستويات عالية من الكوليسترول وتتناول علاجًا يدعى &quot; فصادة البروتينات الدهنية منخفضة الكثافة ( LDL ) &quot; .</li><li dir="rtl">&nbsp;يجب أن تخبري طبيبك إذا كنتِ تعتقدين أنك حامل (أو قد تصبحين حاملاً). لا يوصى باستعمال زستريل في الفترة الأولى من الحمل، ويجب عدم تناوله في حال مضى على الحمل أكثر من 3 أشهر إذ قد يُحدث ضررًا بالغًا على الطفل إذا تم استعماله في هذه المرحلة(انظري قسم الحمل).</li><li dir="rtl">إذا كنت من ذوي البشرة السوداء حيث إن زستريل قد يكون أقل فعالية. وقد تكون أيضًا أكثر عرضة للإصابة بشكل أسرع بالأثر الجانبي &quot; الوذمة الوعائية &quot; (تفاعل تحسسي حاد). إذا لم تكن متأكدًا ما إذا كان أيا من هذه ينطبق عليك، فتحدّث إلى طبيبك أو الصيدلي الخاص<br />بك قبل تناول زستريل.</li></ul><p><strong>علاج حالات الحساسية مثل لدغ الحشرات:</strong><br />أخبر طبيبك إذا كنت تتناول أو تعتزم أن تتناول علاجًا لتخفيف حدة آثار أي نوع من الحساسية مثل لدغ الحشرات (المعالجة الخاصة بخفض الحساسية). إذا تناولت زستريل أثناء تناول هذا العلاج، فقد يسبب تفاع لا تحسسيًا حادًا.<br /><strong>العمليات:</strong><br />إذا كنت تعتزم إجراء عملية (بما في ذلك جراحات الأسنان)، فأخبر طبيبك أو طبيب الأسنان الخاص بك بأنك تتناول زستريل. يعود ذلك إلى أنك قد تصاب بانخفاض في ضغط الدم إذا تم تخديرك موضعيًا أو عامًا أثناء تناول زستريل.<br /><strong>الأطفال والمراهقين</strong><br />تمت دراسة زستريل في الأطفال. لمزيد من المعلومات، تحدث إلى طبيبك الخاص بك. لا ينصح بتناول زستريل للأطفال من هم دون 6 سنوات من العمر أو الأطفال الذين يعانون من مشاكل حادّة في الكلى.<br /><strong>الأدوية الأخرى و زستريل:</strong><br />أخبر طبيبك الخاص بك إذا كنت تتناول أو إذا تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. يعود ذلك إلى أن زستريل قد يؤثر على طريقة عمل بعض الأدوية كما قد يكون لبعض الأدوية تأثير على زستريل.</p><p><br />تحدث إلى طبيبك أو الصيدلي على وجه الخصوص، إذا كنت تتناول أيًا من الأدوية التالية :</p><ul><li>الأدوية الأخرى لعلاج ارتفاع ضغط الدم )الأدوية الخافضة للضغط( بما في ذلك حاصرات&nbsp;مستقبلات الأنجيوتنسين 2 (ARB)&nbsp;أو أليسكيرين، (انظر أيضًا المعلومات الموجودة تحت&nbsp;العناوين &quot;لا تتناول زيستريل&quot; و &quot;توخ الحذر مع زيستريل&quot;).</li><li>&nbsp;الأدوية التي تحتوي على اليسكيرين (لعلاج ارتفاع ضغط الدم).</li><li>&nbsp;أدوية مدرة للبول (أقراص الماء ).</li><li>أدوية تعمل على تذويب جلطات الدم (توصف عادة في المستشفى).</li><li>&nbsp;أدوية حاصرات بيتا، مثل أتينولول وبروبرانولول.</li><li>&nbsp;أدوية النترات (لمشكلات القلب).</li><li>&nbsp;أدوية مضادة للالتهابات غير ستيرويدية ( NSAIDs ) تستخدم لعلاج الألم والتهاب المفاصل.</li><li>&nbsp;أسبرين (حمض الأسيتيل ساليساليك)، إذا كنت تتناول أكثر من 3 جرامات كل يوم.</li><li>&nbsp;الأدوية التي تستخدم لعلاج الاكتئاب والمشكلات العقلية، بما في ذلك الليثيوم.</li><li>&nbsp;مكملات البوتاسيوم، التي تحتوي على البوتاسيوم أو العقاقير الأخرى التي يمكن أن تزيد من&nbsp;البوتاسيوم في جسمك.</li><li>&nbsp;الإنسولين أو الأدوية التي تتناولها عن طريق الفم لعلاج مرض السكري.</li><li>أدوية علاج السرطان )مثل إيفيروليموس( وأدوية تعطى لمنع الجسم من رفض العضو&nbsp;المزروع، على سبيل المثال الكلى أو الكبد (مثل تمسيروليموس، سيروليموس).</li><li>راسيكادوتريل المستخدمة لعلاج الإسهال.</li><li>منشط البلازمينوجين النسيجي (TPA)&nbsp;الذي يستخدم لإذابة الجلطات الدموية التي تكونت في&nbsp;الأوعية الدموية .</li><li>&nbsp;الأدوية المستخدمة في علاج الربو.</li><li>&nbsp;الأدوية المستخدمة لعلاج احتقان الأنف أو الجيوب الأنفية أو علاجات البرد الأخرى (بما في ذلك تلك الأدوية التي يمكنك شراؤها من الصيدلية).</li><li>&nbsp;الأدوية المستخدمة لتثبيط الاستجابة المناعية للجسم (مثبطات المناعة).</li><li>&nbsp;ألوبورينول (للنقرس).</li><li>&nbsp;بروكيناميد (لعلاج مشكلات ضربات القلب).</li><li>&nbsp;الأدوية التي تحتوي على الذهب، مثل أوروثيومالات الصوديوم، والتي قد توصف لك كحقنة.</li></ul><p><strong>الحمل والرضاعة:<br />الحمل :</strong><br />يجب أن تخبري طبيبك إذا كنتِ تعتقدين أنك حامل (أو قد تصبحين حاملاً). عادة ما سينصحكِ الطبيب بالتوقف عن تناول زستريل قبل أن تصبحي حام لا أو بمجرد أن تعرفي أنك أصبحت حامل وسوف ينصحكِ بتناول دواء آخر بد لا من زستريل. لا يوصى باستعمال زستريل في<br />الفترة الأولى من الحمل، ويجب عدم تناوله إذا مضى على أكثر الحمل 3 أشهر، لأنه قد يُحدث ضررًا بالغًا على الطفل إذا تم استعماله بعد مرور الشهر الثالث من الحمل.<br /><strong>الرضاعة :</strong></p><p>أخبري الطبيب إذا كنتِ ترضعين أو على وشك بدء الرضاعة. لا يوصى باستعمال زستريل للأمهات اللواتي يرضعن، وقد يختار الطبيب لكِ علاجًا آخر إذا كنتِ ترغبين في الرضاعة الطبيعية، لا سيما إذا كان الطفل حديث الولادة أو من الأطفال الخُدّج.<br /><strong>القيادة واستخدام الآلات:</strong></p><ul><li>&nbsp;بعض الأشخاص يشعرون بدوار أو بتعب أثناء تناول هذا الدواء. وإذا حدث ذلك لك، فلا تقم بالقيادة أو تستخدم أية أدوات أو آلات.</li><li>&nbsp;يجب عليك الانتظار حتى ترى ما إذا كان الدواء يؤثر عليك أم لا قبل محاولة ممارسة هذه النشاطات.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>يتعيّن عليك تناول هذا الدواء دائمًا وفقًا لتوجيهات الطبيب. تحقق من طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكّدًا.</p><p>بمجرد البدء بتناول زستريل، قد يقوم طبيبك بإجراء اختبارات دم لك. ومن ثم، قد يقوم بتعديل الجرعة حتى تتناول الكمية الصحيحة من الدواء بما يتناسب مع حالتك.</p><p><strong>تناول الدواء:</strong></p><ul><li>&nbsp;ابتلع القرص مع شربة ماء.</li><li>&nbsp;حاول تناول القرص في الوقت ذاته يوميًا. لا يهم إذا تناولت زستريل قبل الطعام أو بعده.</li><li>&nbsp;استمر بتناول زستريل طالما أن الطبيب طلب منك ذلك، فهو علاج طويل المدى. من المهم الالتزام بتناول زستريل يوميًا.</li></ul><p><strong>تناول الجرعة الأولى:</strong></p><ul><li>&nbsp;توخّ الحذر الشديد عند تناولك الجرعة الأولى من زستريل أو إذا زادت جرعتك. فقد يسبب ذلك انخفاضًا مفرطًا في ضغط الدم أكثر من الجرعات اللاحقة.</li><li>&nbsp;قد يجعلك الدواء تشعر بالدوار أو الدوخة. إذا حدث ذلك، قد يساعدك الاسترخاء والحصول على بعض الراحة. وإذا كنت قلقًا، فيرجى التحدث إلى الطبيب في أسرع وقت ممكن.</li></ul><p><strong>البالغون:</strong><br />تعتمد الجرعة التي تتناولها على حالتك الطبية وعلى ما إذا كنت تتناول أدوية أخرى أم لا. سيطلعك طبيبك على عدد الأقراص التي يتوجب أن تتناولها يوميًا. تحقق من طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكّدًا.<br /><strong>بالنسبة لضغط الدم المرتفع:</strong></p><ul><li>&nbsp;تبلغ جرعة البداية الموصّى بها 10 ملجم مرة واحدة يوميًا.</li><li>&nbsp;تبلغ الجرعة طويلة المدى الاعتيادية 20 ملجم مرة واحدة يوميًا.</li></ul><p><strong>بالنسبة لفشل القلب:</strong></p><ul><li>&nbsp;تتراوح الجرعة طويلة المدى بين 5 و 35 ملجم مرة واحدة يوميًا.</li></ul><p><strong>بعد نوبة قلبية:</strong></p><ul><li>&nbsp;تبلغ جرعة البداية الموصّى بها 5 ملجم في غضون 24 ساعة من النوبة و 5 ملجم بعد يوم من حدوثها.</li><li>&nbsp;تبلغ الجرعة طويلة المدى الاعتيادية 10 ملجم مرة واحدة يوميًا.</li></ul><p><strong>بالنسبة لمشكلات الكلى الناجمة عن مرض السكري:</strong></p><ul><li>&nbsp;تبلغ الجرعة الموصّى بها 10 ملجم أو 20 ملجم مرة واحدة يوميًا.</li></ul><p>وإذا كنت كبير في السن وتعاني من مشكلات في الكلى أو تتناول أدوية مدرة للبول، فقد يصف<br />لك الطبيب جرعة أقل من الجرعة الاعتيادية.<br /><strong>الاستخدام مع الأطفال والمراهقون (من 6 إلى 16 سنة) الذين يعانون من ارتفاع ضغط الدم:</strong></p><ul><li>&nbsp;لا يوصى باستعمال زستريل للأطفال الذين يقل عمرهم عن 6 سنوات أو أي أطفال يعانون من مشكلات حادة في الكلى.</li><li>&nbsp;سيقوم الطبيب بوصف الجرعة الصحيحة التي تناسب طفلك. تعتمد الجرعة على وزن الطفل.</li><li>&nbsp;بالنسبة للأطفال الذين يتخطى وزنهم 50 كلجم، تبلغ جرعة البداية الموصّى بها 5 ملجم مرة واحدة يوميًا.</li></ul><p><strong>إذا تناولت جرعة من زستريل أكثر مما ينبغي:</strong><br />إذا تناولت جرعة زائدة من زستريل أكثر مما وُصِفَ لك، فتحدث إلى طبيب أو توجه نحو مستشفى على الفور. التأثيرات التالية هي الأكثر احتما لا أن تحدث : دوار أو خفقان.<br /><strong>إذا نسيت تناول زستريل:</strong></p><ul><li>&nbsp;إذا نسيت تناول إحدى الجرعات، فتناولها بمجرد تذكُرك إياها. ومع ذلك، إذا اقترب وقت الجرعة التالية، فلا تتناول الجرعة المنسية.</li><li>&nbsp;لا تتناول جرعة مزدوجة لتعويض جرعة فائتة.</li></ul><p><strong>إذا توقفت عن تناول زستريل:</strong><br />لا تتوقف عن تناول أقراصك، حتى عند الشعور بتحسن، إلا إذا طلب منك الطبيب ذلك.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فتحدث إلى طبيبك أو الصيدلي الخاص بك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>كما هو الحال في جميع الأدوية، قد يتسبّب هذا الدواء بحدوث آثار جانبية على الرغم من أنها لا تصيب جميع المستخدمين.</p><p>إذا واجهت أحد التفاعلات التالية، <strong>فتوقف عن تناول زستريل واستشر طبيبك على الفور :</strong></p><ul><li>&nbsp;تفاعلات تحسسية حادة (نادرة، تؤثر على مستخدم واحد إلى عشرة مستخدمين من أصل 10000 مستخدم). قد تتضمن العلامات ظهورًا مفاجئًا ل :</li></ul><p>- تورم الوجه أو الشفتين أو اللسان أو الحلق. قد يسبب ذلك صعوبة في البلع.<br />- تورم حاد أو مفاجئ لليدين والقدمين والكاحلين.<br />- صعوبة في التنفس.<br />- حكة جلدية شديدة (مع ظهور بثور مرتفعة عن سطح الجلد).</p><ul><li>&nbsp;اضطرابات جلدية حادة، مثل طفح أو حرق جلدي مفاجئ أو غير متوقع، واحمرار الجلد أو تقشره (نادرة جدًا، تؤثر في أقل من مستخدم واحد في كل 10000 مستخدم).</li><li>&nbsp;عدوى مصاحبة لأعراض مثل حمى وتدهور حاد في الحالة العامة أو حمى مصاحبة لأعراض عدوى موضعية مثل احتقان الحلق / البلعوم / الفم أو مشكلات في الجهاز البولي (نادرة جدًا، تؤثر في أقل من مستخدم واحد في كل 10000 مستخدم).</li></ul><p><strong>الآثار الجانبية المحتملة الأخرى :<br />&nbsp;شائعة (تؤثّر في عدد يتراوح بين مستخدم إلى عشرة مستخدمين من أصل 100):</strong></p><ul><li>&nbsp;صداع.</li><li>&nbsp;الشعور بدوار أو دوخة</li><li>&nbsp;إسهال.</li><li>&nbsp;سعال جاف دائم لا يزول.</li><li>&nbsp;شعور بالمرض (تقيؤ).</li><li>&nbsp;مشكلات في الكلى (تظهر في اختبار دم).</li></ul><p><strong>غير شائعة (تؤثّر في عدد يتراوح بين مستخدم إلى عشرة مستخدمين من أصل 1000):</strong></p><ul><li>&nbsp;تغيرات في المزاج.</li><li>&nbsp;تغير في لون أصابع اليدين أو القدمين (لون أزرق شاحب يتبعه احمرار) أو تنميل أو وخز أصابع اليدين أو القدمين.</li><li>&nbsp;تغير في حاسة الذوق.</li><li>&nbsp;الشعور بالنعاس.</li><li>&nbsp;شعور بالدوار.</li><li>&nbsp;المعاناة من صعوبة في النوم.</li><li>&nbsp;سكتة دماغية.</li><li>&nbsp;سرعة ضربات القلب.</li><li>&nbsp;رشح الأنف.</li><li>&nbsp;الشعور بالمرض (الغثيان).</li><li>&nbsp;ألم في المعدة أو عسر هضم.</li><li>&nbsp;طفح جلدي أو حكة.</li><li>&nbsp;عدم القدرة على الانتصاب (عجز جنسي).</li><li>&nbsp;الشعور بالتعب أو الضعف (فقد القوة).</li><li>&nbsp;قد يحدث انخفاض كبير جدًا في ضغط الدم لدى الأشخاص الذين يعانون من الحالات التالية : مرض قلب تاجي؛ ضيق في الأبهر (شريان في القلب) أو الشريان الكلوي أو صمامات القلب؛ زيادة في كثافة عضلة القلب. في حال حدوث ذلك، قد تشعر بدوار أو دوخة لا سيما إذا حاولت الوقوف بسرعة.</li><li>&nbsp;تغيرات في اختبارات الدم التي تبين مدى سلامة عمل الكبد والكلى.</li><li>&nbsp;نوبة قلبية.</li><li>&nbsp;شوهد أو سُمع ببعض حالات الهلوسة.</li></ul><p><strong>نادرة (تؤثّر في عدد يتراوح بين مستخدم إلى عشرة مستخدمين من أصل 100000)</strong></p><ul><li>&nbsp;الشعور بالارتباك.</li><li>&nbsp;طفح جلدي كتلي (الشرى).</li><li>&nbsp;جفاف الفم.</li><li>&nbsp;تساقط الشعر.</li><li>&nbsp;الصُداف (مشكلة بالجلد).</li><li>&nbsp;تغير في حاسة الشم.</li><li>&nbsp;تطور نمو الثديين عند الرجال.</li><li>&nbsp;تغييرات في بعض خلايا الجسم أو في أجزاء أخرى منه. قد يأخذ الطبيب عينات دم من وقتٍ لآخر للتحقق مما إذا كان لزستريل أي تأثير على الدم. قد تتضمن هذه العلامات&nbsp;الشعور بالتعب أو بشرة شاحبة أو احتقان في الحلق أو ارتفاع في درجة الحرارة (حمى) أو ألم في المفاصل والعضلات أو تورم في المفاصل أو الغدد أو حساسية تجاه ضوء الشمس.</li><li>&nbsp;انخفاض مستويات الصوديوم في الدم (قد تتضمن الأعراض التعب والصداع والغثيان والتقيؤ).</li><li>&nbsp;فشل كلوي مفاجئ.</li></ul><p><strong>نادرة جدًا (تصيب أقل من مستخدم واحد في كل 10000):</strong></p><ul><li>&nbsp;التهاب الجيوب الأنفية (شعور بالألم والامتلاء خلف وجنتيك وعينيك).</li><li>&nbsp;أزيز بالصدر.</li><li>&nbsp;انخفاض مستويات السكر في الدم (نقص السكر في الدم). قد تتضمن العلامات الشعور بالجوع أو الضعف، والتعرّق وسرعة ضربات القلب.</li><li>&nbsp;التهاب الرئتين. علامات تتضمن السعال والشعور بضيق في التنفس وارتفاع في درجة الحرارة (حمى).</li><li>&nbsp;اصفرار الجلد أو الجزء الأبيض من العينين (اليرقان).</li><li>&nbsp;التهاب الكبد. قد يتسبب ذلك في فقدان الشهية واصفرار الجلد والعينين وبول غامق اللون.</li><li>&nbsp;التهاب البنكرياس. يسبب ذلك ألمًا في المعدة يتراوح بين متوسط وحاد.</li><li>&nbsp;اضطرابات حادة في الجلد. تتضمن الأعراض احمرار الجلد أو تبثره أو تقشره.</li><li>&nbsp;التعرّق.</li><li>&nbsp;مرور قدر قليل من الماء (البول) أقل من القدر المعتاد أو عدم مرور الماء بالكلية.</li><li>&nbsp;فشل في الكبد.</li><li>&nbsp;بثور.</li><li>&nbsp;التهاب الأمعاء.</li></ul><p><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتوفرة):</strong></p><ul><li>&nbsp;أعراض الاكتئاب.</li><li>&nbsp;إغماء.</li><li>رد فعل تحسسي شديد</li></ul><p>يبدو أنّ الآثار الجانبية لدى الأطفال مماثلة لتلك التي تظهر لدى البالغين.<br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />إذا شعرت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي الخاص بك. وهذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه). من خلال الإبلاغ عن الآثار الجانبية يمكن أن تساعد على توفير مزيد<br />من المعلومات حول سلامة هذا الدواء. (تستكمل على الصعيد الوطني).</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><ul><li>&nbsp;احتفظ بهذا الدواء بعيدًا عن رؤية و متناول الأطفال.</li><li>&nbsp;أقراص 5 ملجم و 10 ملجم و 20 ملجم : لا تقم بالتخزين في درجة حرارة أعلى من 30 درجة مئوية.</li><li>&nbsp;لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدوّن على الشريط والعلبة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المدوّن.</li><li>&nbsp;لا تتخلص من الأدوية بإلقائها في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي الخاص بك عن إجراءات التخلص من الأدوية التي لم تعد تستعملها. حيث تساعد هذه الإجراءات في حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><ul><li>&nbsp;المادة النشطة هي ليسينوبريل (كثنائي الهيدرات).</li><li>&nbsp;المكونات الأخرى هي مانيتول وثنائي الهيدرات فوسفات هيدروجين الكالسيوم ونشا الذرة ونشا معدّل وستيارات الماغنيسيوم. بالإضافة إلى ذلك، تحتوي الأقراص الزهرية والبنية اللون على أكسيد الحديد الأحمر ( E172) . زستريل متوفر ب 3 تركيزات تحتوي على 5 ملجم أو 10 ملجم أو 20 ملجم من ليسينوبريل (كثنائي الهيدرات).</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص زستريل 5 ملجم : قرص مستدير زهري اللون غير مغلف ومحدب الوجهين، مطبوع على أحد جانبيه &quot;&hearts; 5&quot; والجانب الآخر مقسوم. قطر القرص 6 ملم. يمكن تقسيم القرص إلى جرعات متساوية. أقراص زستريل 11 ملجم : قرص مستدير زهري اللون غير مغلف ومحدب الوجهين، مطبوع على أحد جانبيه &quot;&hearts; 10&quot; والجانب الآخر ممسوح. قطر القرص 8 ملم. أقراص زستريل 21 ملجم : قرص مستدير بني اللون غير مغلف ومحدب الوجهين، مطبوع على أحد جانبيه &quot;&hearts; 20&quot; والجانب الآخر ممسوح. قطر القرص 8 ملم. تتوفر أقراص زستريل في عبوات بأشرطة مصنوعة من رقائق الألومنيوم تحتوي على 28 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>تراخيص التسويق لعقار زستريل مملوكة في شركة AstraZeneca المحدودة في المملكة</p><p>المتحدة، والكائنة في 600 Capability Green, Luton, LU1 3LU, UK .</p><p>يتم تصنيع زستريل من خلال شركة AstraZeneca المحدودة في المملكة المتحدة Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA ، المملكة المتحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             أبريل 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zestril 5 mg, 10 mg, and 20 mg tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains lisinopril dihydrate equivalent to 5 mg, 10 mg, or 20 mg anhydrous lisinopril.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 mg tablets: round, pink, uncoated, biconvex tablet with “♥ 5” on one side and bisected on the other side. Diameter 6 mm.
The tablet can be divided into equal doses.
10 mg tablets: round, pink, uncoated, biconvex tablet with “♥ 10” on one side and plain on the other side. Diameter 8 mm.
20 mg tablets: round, brownish-red, uncoated, biconvex tablet with “♥ 20” on one side and plain on the other side. Diameter 8 mm.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Hypertension</strong><br />Treatment of hypertension.</p><p><strong>Heart failure</strong><br />Treatment of symptomatic heart failure.<br /><strong>Acute myocardial infarction</strong><br />Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction.<br /><strong>Renal complications of diabetes mellitus</strong><br />Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zestril should be administered orally in a single daily dose. As with all other medication taken once daily, Zestril should be taken at approximately the same time each day. The absorption of Zestril tablets is not affected by food.<br />The dose should be individualised according to patient profile and blood pressure response (see section 4.4).<br /><strong>Hypertension</strong><br />Zestril may be used as monotherapy or in combination with other classes of antihypertensive therapy.</p><p><u>Starting dose</u><br />In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 2.5-5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. A lower starting dose is required in the presence of renal impairment (see Table 1 below).<br /><u>Maintenance dose</u><br />The usual effective maintenance dosage is 20 mg administered in a single daily dose. In general, if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level, the dose can be further increased. The maximum dose used in long-term, controlled clinical trials was 80 mg/day.<br /><u>Diuretic-treated patients</u><br />Symptomatic hypotension may occur following initiation of therapy with Zestril. This is more likely in patients who are being treated currently with diuretics. Caution is recommended therefore, since these patients may be volume and/or salt depleted. If possible, the diuretic should be discontinued 2 to 3 days before beginning therapy with Zestril. In hypertensive patients in whom the diuretic cannot&nbsp;be discontinued, therapy with Zestril should be initiated with a 5 mg dose. Renal function and serum potassium should be monitored. The subsequent dosage of Zestril should be adjusted according to blood pressure response. If required, diuretic therapy may be resumed (see section 4.4 and section 4.5).</p><p><u>Dosage adjustment in renal impairment</u><br />Dosage in patients with renal impairment should be based on creatinine clearance as outlined in Table 1 below.</p><p><strong>Table 1 Dosage adjustment in renal impairment</strong></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><strong>Creatinine Clearance (ml/min)</strong></td><td><strong>Starting Dose (mg/day)</strong></td></tr><tr><td>Less than 10 ml/min (including patients on dialysis)</td><td>2.5 mg*</td></tr><tr><td>10-30 ml/min</td><td>2.5-5 mg</td></tr><tr><td>31-80 ml/min</td><td>5-10 mg</td></tr></tbody></table><p>* Dosage and/or frequency of administration should be adjusted depending on the blood pressure response.</p><p>The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.<br /><u>Use in hypertensive paediatric patients aged 6&ndash;16 years</u><br />The recommended initial dose is 2.5 mg once daily in patients 20 to &lt;50 kg, and 5 mg once daily in patients &ge;50 kg. The dosage should be individually adjusted to a maximum of 20 mg daily in patients weighing 20 to &lt;50 kg, and 40 mg in patients &ge;50 kg. Doses above 0.61 mg/kg (or in excess of 40 mg) have not been studied in paediatric patients (see section 5.1).</p><p><br />In children with decreased renal function, a lower starting dose or increased dosing interval should be considered.</p><p><strong>Heart failure</strong><br />In patients with symptomatic heart failure, Zestril should be used as adjunctive therapy to diuretics and, where appropriate, digitalis or beta-blockers. Zestril may be initiated at a starting dose of 2.5 mg once a day, which should be administered under medical supervision to determine the initial effect on the blood pressure. The dose of Zestril should be increased:</p><ul><li>&nbsp;By increments of no greater than 10 mg</li><li>&nbsp;At intervals of no less than 2 weeks</li><li>&nbsp;To the highest dose tolerated by the patient up to a maximum of 35 mg once daily.</li></ul><p>Dose adjustment should be based on the clinical response of individual patients. Patients at high risk of symptomatic hypotension, e.g. patients with salt depletion with or without hyponatraemia, patients with hypovolaemia or patients who have been receiving vigorous diuretic therapy should have these conditions corrected, if possible, prior to therapy with Zestril. Renal function and serum potassium should be monitored (see section 4.4).</p><p><strong>Acute myocardial infarction</strong><br />Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin, and beta-blockers. Intravenous or transdermal glyceryl trinitrate may be used together with Zestril.<br /><u>Starting dose (first 3 days after infarction)</u><br />Treatment with Zestril may be started within 24 hours of the onset of symptoms. Treatment should not be started if systolic blood pressure is lower than 100 mm Hg. The first dose of Zestril is 5 mg given orally, followed by 5 mg after 24 hours, 10 mg after 48 hours and then 10 mg once daily. Patients with a low systolic blood pressure (120 mm Hg or less) when treatment is started or during the first 3 days after the infarction should be given a lower dose - 2.5 mg orally (see section 4.4).<br />In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Zestril dosage should be adjusted according to the patient&rsquo;s creatinine clearance (see Table 1).<br /><u>Maintenance dose</u><br />The maintenance dose is 10 mg once daily. If hypotension occurs (systolic blood pressure less than or equal to 100 mm Hg) a daily maintenance dose of 5 mg may be given with temporary reductions to 2.5 mg if needed. If prolonged hypotension occurs (systolic blood pressure less than 90 mm Hg for more than 1 hour) Zestril should be withdrawn.<br />Treatment should continue for 6 weeks and then the patient should be re-evaluated. Patients who develop symptoms of heart failure should continue with Zestril (see section 4.2).</p><p><u>Renal complications of diabetes mellitus</u><br />In hypertensive patients with type 2 diabetes mellitus and incipient nephropathy, the dose is 10 mg Zestril once daily which can be increased to 20 mg once daily, if necessary, to achieve a sitting diastolic blood pressure below 90 mm Hg.<br />In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Zestril dosage should be adjusted according to the patient&rsquo;s creatinine clearance (see Table 1).</p><p><strong>Paediatric population</strong></p><p>There is limited efficacy and safety experience in hypertensive children &gt;6 years old, but no experience in other indications (see section 5.1). Zestril is not recommended in children in other indications than hypertension.<br />Zestril is not recommended in children below the age of 6, or in children with severe renal impairment (GFR &lt;30ml/min/1.73m2) (see section 5.2).</p><p><strong>Older people</strong><br />In clinical studies, there was no age-related change in the efficacy or safety profile of the drug. When advanced age is associated with decrease in renal function, however, the guidelines set out in Table 1 should be used to determine the starting dose of Zestril. Thereafter, the dosage should be adjusted according to the blood pressure response.<br /><strong>Use in kidney transplant patients</strong><br />There is no experience regarding the administration of Zestril in patients with recent kidney transplantation. Treatment with Zestril is therefore not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to Zestril, to any of the excipients listed in section 6.1 or any other angiotensin converting enzyme (ACE) inhibitor.
 History of anaphylactic/anaphylactoid reactions or angioedema associated with previous ACE inhibitor therapy.
 Hereditary or idiopathic angioedema.
 Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
 In combination with aliskiren-containing medicines in patients with diabetes mellitus (type I or II) or with moderate to severe renal impairment (GFR < 60ml/min/1.73m2).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptomatic hypotension</strong><br />Symptomatic hypotension is seen rarely in uncomplicated hypertensive patients. In hypertensive patients receiving Zestril, hypotension is more likely to occur if the patient has been volume-depleted, e.g. by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting, or has severe renin-dependent hypertension (see section 4.5 and section 4.8). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In patients at increased risk of symptomatic hypotension, initiation of therapy and dose adjustment should be closely monitored. Similar considerations apply to patients with ischaemic heart or cerebrovascular disease in&nbsp;whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.&nbsp;</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.<br />In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with Zestril. This effect is anticipated and is not usually a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose or discontinuation of Zestril may be necessary.</p><p><strong>Hypotension in acute myocardial infarction</strong><br />Treatment with Zestril must not be initiated in acute myocardial infarction patients who are at risk of further serious haemodynamic deterioration after treatment with a vasodilator. These are patients with systolic blood pressure of 100 mm Hg or lower, or those in cardiogenic shock. During the first 3 days following the infarction, the dose should be reduced if the systolic blood pressure is 120 mm Hg or lower. Maintenance doses should be reduced to 5 mg or temporarily to 2.5 mg if systolic blood pressure is 100 mm Hg or lower. If hypotension persists (systolic blood pressure less than 90 mm Hg for more than 1 hour) then Zestril should be withdrawn.</p><p><strong>Aortic and mitral valve stenosis / hypertrophic cardiomyopathy</strong><br />As with other ACE inhibitors, Zestril should be given with caution to patients with mitral valve stenosis and obstruction in the outflow of the left ventricle such as aortic stenosis or hypertrophic cardiomyopathy.<br /><strong>Renal function impairment</strong><br />In cases of renal impairment (creatinine clearance &lt;80 ml/min), the initial Zestril dosage should be adjusted according to the patient&rsquo;s creatinine clearance (see Table 1 in section 4.2), and then as a function of the patient&rsquo;s response to treatment. Routine monitoring of potassium and creatinine is part of normal medical practice for these patients.<br />In patients with<u> heart failure</u>, hypotension following the initiation of therapy with ACE inhibitors may lead to some further impairment in renal function. Acute renal failure, usually reversible, has been reported in this situation.<br />In some patients with <u>bilateral renal artery stenosis or with a stenosis of the artery to a solitary kidney,</u> who have been treated with angiotensin-converting enzyme inhibitors, increases in blood urea and serum creatinine, usually reversible upon discontinuation of therapy, have been seen. This is especially likely in patients with&nbsp;renal insufficiency. If renovascular hypertension is also present there is an increased risk of severe hypotension and renal insufficiency. In these patients, treatment should be started under close medical supervision with low doses and careful dose titration. Since treatment with diuretics may be a contributory factor to the above, they should be discontinued and renal function should be monitored during the first weeks of Zestril therapy.</p><p>Some<u> hypertensive patients</u> with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when Zestril has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or Zestril may be required.<br />In acute<u> myocardial infarction, </u>treatment with Zestril should not be initiated in patients with evidence of renal dysfunction, defined as serum creatinine concentration exceeding 177 micromol/l and/or proteinuria exceeding 500 mg/24 h. If renal dysfunction develops during treatment with Zestril (serum creatinine concentration exceeding 265 micromol/l or a doubling from the pre-treatment value) then the physician should consider withdrawal of Zestril.</p><p><strong>Hypersensitivity/Angioedema</strong><br />Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin-converting enzyme inhibitors, including Zestril. This may occur at any time during therapy. In such cases, Zestril should be discontinued promptly and appropriate treatment and monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patients. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.<br />Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx, are likely to experience airway obstruction, especially those with a history of airway surgery. In such cases emergency therapy should be administered promptly. This may include the administration of adrenaline and/or the maintenance of a patient&rsquo;s airway. The patient should be under close medical supervision until complete and sustained resolution of symptoms has occurred.<br />Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.<br />Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see section 4.3).</p><p>Some drugs if given concomitantly with ACE inhibitors may increase the risk of angioedema (see section 4.5)</p><p><strong>Anaphylactoid reactions in haemodialysis patients</strong></p><p>Anaphylactoid reactions have been reported in patients dialysed with high flux membranes (e.g. AN 69) and treated concomitantly with an ACE inhibitor. In these patients, consideration should be given to using a different type of dialysis membrane or different class of antihypertensive agent.</p><p><strong>Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis</strong><br />Rarely, patients receiving ACE inhibitors during low-density lipoproteins (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.<br /><strong>Desensitisation</strong><br />Patients receiving ACE inhibitors during desensitisation treatment (e.g. hymenoptera venom) have sustained anaphylactoid reactions. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld but they have reappeared upon inadvertent re-administration of the medicinal product.<br /><strong>Hepatic failure</strong><br />Very rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving Zestril who develop jaundice or marked elevations of hepatic enzymes should discontinue Zestril and receive appropriate medical follow-up.<br /><strong>Neutropenia/Agranulocytosis</strong><br />Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Neutropenia and agranulocytosis are reversible after discontinuation of the ACE inhibitor. Zestril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections, which in a few instances did not respond to intensive antibiotic therapy. If Zestril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.<br /><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with aliskiren-containing medicines</strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of the RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see section 4.3 and 4.5).</p><p>If dual blockade therapy is considered necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong>Race</strong></p><p>Angiotensin-converting enzyme inhibitors cause a higher rate of angioedema in black patients than in non-black patients.<br />As with other ACE inhibitors, Zestril may be less effective in lowering blood pressure in black patients than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p><p><strong>Cough</strong><br />Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is non-productive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.<br /><strong>Surgery/Anaesthesia</strong><br />In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, Zestril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.<br /><strong>Hyperkalaemia</strong><br />Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including Zestril. Patients at risk for the development of hyperkalaemia include those with renal insufficiency, diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes, or those patients taking other drugs associated with increases in serum potassium (e.g. heparin). If concomitant use of the above-mentioned agents is deemed appropriate, regular monitoring of serum potassium is recommended (see section 4.5).<br /><strong>Diabetic patients</strong><br />In diabetic patients treated with oral antidiabetic agents or insulin, glycaemic control should be closely monitored during the first month of treatment with an ACE inhibitor (see 4.5 Interaction with other medicinal products and other forms of interaction).<br /><strong>Lithium</strong><br />The combination of lithium and Zestril is generally not recommended (see section 4.5).<br /><strong>Pregnancy</strong><br />ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Antihypertensive agents</strong><br />When Zestril is combined with other antihypertensive agents (e.g. glyceryl trinitrate and other nitrates, or other vasodilators), additive falls in blood pressure may occur.</p><p>Clinical trial data has shown that dual blockade of (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal&nbsp;function (including acute renal failure) compared to the use of a single RAAS-acting agent.</p><p>Drugs that may increase the risk of angioedema Concomitant treatment of ACE inhibitors with mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus, sirolimus, everolimus) or neutral endopeptidase (NEP) inhibitors (e.g. racecadotril) 5 or tissue plasminogen activator may increase the risk of angioedema.</p><p><strong>Diuretics</strong><br />When a diuretic is added to the therapy of a patient receiving Zestril the antihypertensive effect is usually additive.<br />Patients already on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure when Zestril is added. The possibility of symptomatic hypotension with Zestril can be minimised by discontinuing the diuretic prior to initiation of treatment with Zestril (see section 4.4 and section 4.2).</p><p><br /><strong>Potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes&nbsp;and other drugs that may increase serum potassium levels</strong></p><p>Although in clinical trials, serum potassium usually remained within normal limits, hyperkalaemia did occur in some patients. Risk factors for the development of hyperkalaemia include renal insufficiency, diabetes mellitus, and concomitant use of potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes other drugs that<br />may increase serum potassium levels (heparin, co-trimoxazole).<br />The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes and other drugs that may increase serum potassium levels, particularly in patients with impaired renal function, may lead to a significant increase in serum potassium. If Zestril is given with a potassium-losing diuretic, diuretic-induced hypokalaemia may be ameliorated.</p><p><strong>Lithium</strong><br />Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased lithium toxicity with ACE inhibitors. Use of Zestril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p><br /><strong>Non-steroidal anti-inflammatory medicinal products (NSAIDs) including acetylsalicylic acid </strong>&ge;<strong> 3 g/day</strong><br />When ACE-inhibitors are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE-inhibitors and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. These effects are usually reversible. The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p><br /><strong>Gold</strong><br />Nitritoid reactions (symptoms of vasodilatation including flushing, nausea, dizziness and hypotension, which can be very severe) following injectable gold (for example, sodium aurothiomalate) have been reported more frequently in patients receiving ACE inhibitor therapy.</p><p><br /><strong>Tricyclic antidepressants / Antipsychotics / Anaesthetics</strong><br />Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p><br /><strong>Sympathomimetics</strong><br />Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p><br /><strong>Antidiabetics</strong><br />Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood glucose-lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment.</p><p><strong>Acetylsalicylic acid, thrombolytics, beta-blockers, nitrates</strong><br />Zestril may be used concomitantly with acetylsalicylic acid (at cardiologic doses), thrombolytics, beta-blockers and/or nitrates.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see section 4.4). The use of ACE inhibitors is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitors therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p><br />Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).</p><p><br />Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p><br />Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p><br /><strong>Breastfeeding</strong><br />Because no information is available regarding the use of Zestril during breast-feeding, Zestril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following undesirable effects have been observed and reported during treatment with Zestril and other ACE inhibitors with the following frequencies: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p><strong>Blood and the lymphatic system disorders</strong><br />rare: decreases in haemoglobin, decreases in haematocrit<br />very rare: bone marrow depression, anaemia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis (see section 4.4), haemolytic anaemia, lymphadenopathy, autoimmune disease.<br /><strong>Metabolism and nutrition disorders</strong><br />very rare: hypoglycaemia.<br /><strong>Nervous system and psychiatric disorders</strong><br />common: dizziness, headache<br />uncommon: mood alterations, paraesthesia, vertigo, taste disturbance, sleep disturbances, hallucinations.<br />rare: mental confusion, olfactory disturbance<br />frequency not known: depressive symptoms, syncope.<br /><strong>Cardiac and vascular disorders</strong><br />common: orthostatic effects (including hypotension)<br />uncommon: myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see section 4.4), palpitations, tachycardia, Raynaud&rsquo;s phenomenon.<br /><strong>Respiratory, thoracic and mediastinal disorders</strong><br />common: cough<br />uncommon: rhinitis<br />very rare: bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia.<br /><strong>Gastrointestinal disorders</strong><br />common: diarrhoea, vomiting<br />uncommon: nausea, abdominal pain and indigestion<br />rare: dry mouth<br />very rare: pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or cholestatic, jaundice and hepatic failure (see section 4.4).<br /><strong>Skin and subcutaneous tissue disorders</strong><br />uncommon: rash, pruritus</p><p>rare: urticaria, alopecia, psoriasis, hypersensitivity/angioneurotic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis, and/or larynx (see section 4.4)<br />very rare: sweating, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, cutaneous pseudolymphoma.<br />A symptom complex has been reported which may include one or more of the following: fever, vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies (ANA), elevated red blood cell sedimentation rate (ESR), eosinophilia and leucocytosis, rash, photosensitivity or other dermatological manifestations may occur.</p><p><strong>Renal and urinary disorders</strong><br />common: renal dysfunction<br />rare: uraemia, acute renal failure<br />very rare: oliguria/anuria.<br /><strong>Endocrine disorders</strong><br />rare: syndrome of inappropriate antidiuretic hormone secretion (SIADH).<br />Reproductive system and breast disorders<br />uncommon: impotence<br />rare: gynaecomastia.<br /><strong>General disorders and administration site conditions</strong><br />uncommon: fatigue, asthenia.<br /><strong>Investigations</strong><br />uncommon: increases in blood urea, increases in serum creatinine, increases in liver enzymes, hyperkalaemia<br />rare: increases in serum bilirubin, hyponatraemia.<br />Safety data from clinical studies suggest that lisinopril is generally well tolerated in hypertensive paediatric patients, and that the safety profile in this age group is comparable to that seen in adults.</p><p><strong>Post marketing</strong><br />Immune system disorders:<br />not known anaphylactic/anaphylactoid reaction</p><p>To report any side effect(s):<br /><strong>&nbsp;Saudi Arabia:</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p><strong>Other GCC states:</strong></p><p>- Please contact the relevant competent authority.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. [To be completed nationally]</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available for overdose in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.<br />The recommended treatment of overdose is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating Zestril (e.g. emesis, gastric lavage, administration of absorbents and sodium sulphate). Zestril may be removed from the general circulation by haemodialysis (see section 4.4). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored frequently.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin-converting enzyme inhibitors, ATC code: C09A A03.<br /><strong>Mechanism of Action</strong><br />Zestril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin-converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of angiotensin&nbsp;II which results in decreased vasopressor activity and reduced aldosterone secretion. The latter decrease may result in an increase in serum potassium concentration.</p><p><strong>Pharmacodynamic effects</strong><br />Whilst the mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, lisinopril is antihypertensive even in patients with low renin hypertension. ACE is identical to kininase II, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodilatory peptide, play a role in the therapeutic effects of lisinopril remains to be elucidated.</p><p><strong>Clinical efficacy and safety</strong><br />The effect of Zestril on mortality and morbidity in heart failure has been studied by comparing a high dose (32.5 mg or 35 mg once daily) with a low dose (2.5 mg or 5 mg once daily). In a study of 3164 patients, with a median follow-up period of 46 months for surviving patients, high dose Zestril produced a 12% risk reduction in the combined endpoint of all-cause mortality and all-cause hospitalisation (p = 0.002) and an 8% risk reduction in all-cause mortality and cardiovascular hospitalisation (p = 0.036) compared with low dose. Risk reductions for all-cause mortality (8%; p = 0.128) and cardiovascular mortality (10%; p = 0.073) were observed. In a post-hoc analysis, the number of hospitalisations for heart failure was reduced by 24% (p=0.002) in patients treated with high-dose Zestril compared with low dose. Symptomatic benefits were similar in patients treated with high and low doses of Zestril.<br />The results of the study showed that the overall adverse event profiles for patients treated with high or low dose Zestril were similar in both nature and number. Predictable events resulting from ACE inhibition, such as hypotension or altered renal function, were manageable and rarely led to treatment withdrawal. Cough was less frequent in patients treated with high dose Zestril compared with low dose.<br />In the GISSI-3 trial, which used a 2x2 factorial design to compare the effects of Zestril and glyceryl trinitrate given alone or in combination for 6 weeks versus control in 19,394 patients who were administered the treatment within 24 hours of an acute myocardial infarction, Zestril produced a statistically significant risk reduction in mortality of 11% versus control (2p=0.03). The risk reduction with glyceryl trinitrate was not significant but the combination of Zestril and glyceryl trinitrate produced a significant risk reduction in mortality of 17% versus control (2p=0.02). In the sub-groups of elderly (age &gt; 70 years) and females, pre-defined as patients at high risk of mortality, significant benefit was observed for a combined endpoint of mortality and cardiac function. The combined endpoint for all patients, as well as the high-risk sub-groups at 6 months, also showed significant benefit for those treated with Zestril or Zestril plus glyceryl trinitrate for 6 weeks, indicating a prevention effect for Zestril. As would be expected from any vasodilator treatment,&nbsp;increased incidences of hypotension and renal dysfunction were associated with Zestril treatment but these were not associated with a proportional increase in mortality.</p><p>In a double-blind, randomised, multicentre trial which compared Zestril with a calcium channel blocker in 335 hypertensive Type 2 diabetes mellitus subjects with incipient nephropathy characterised by microalbuminuria, Zestril 10 mg to 20 mg administered once daily for 12 months, reduced systolic/diastolic blood pressure by 13/10 mmHg and urinary albumin excretion rate by 40%. When compared with the calcium channel blocker, which produced a similar reduction in blood pressure, those treated with Zestril showed a significantly greater reduction in urinary albumin excretion rate, providing evidence that the ACE inhibitory action of Zestril reduced microalbuminuria by a direct mechanism on renal tissues in addition to its blood pressure-lowering effect.<br />Lisinopril treatment does not affect glycaemic control as shown by a lack of significant effect on levels of glycated haemoglobin (HbA1c).</p><p><strong>Paediatric population</strong><br />In a clinical study involving 115 paediatric patients with hypertension, aged 6&ndash;16 years, patients who weighed less than 50 kg received either 0.625 mg, 2.5 mg or 20 mg of Zestril once a day, and patients who weighed 50 kg or more received either 1.25 mg, 5 mg or 40 mg of Zestril once a day. At the end of 2 weeks, Zestril administered once daily lowered trough blood pressure in a dose-dependent manner with a consistent antihypertensive efficacy demonstrated at doses greater than 1.25 mg.<br />This effect was confirmed in a withdrawal phase, where the diastolic pressure rose by about 9 mm Hg more in patients randomised to placebo than it did in patients who were randomised to remain on the middle and high doses of Zestril. The dose-dependent antihypertensive effect of Zestril was consistent across several demographic subgroups: age, Tanner stage, gender, and race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lisinopril is an orally active non-sulphydryl-containing ACE inhibitor.<br /><strong>Absorption</strong><br />Following oral administration of lisinopril, peak serum concentrations occur within about 7 hours, although there was a trend to a small delay in time taken to reach peak serum concentrations in acute myocardial infarction patients. Based on urinary recovery, the mean extent of absorption of lisinopril is approximately 25% with interpatient variability of 6-60% over the dose range studied (5-80 mg). The absolute bioavailability is reduced approximately 16% in patients with heart failure. Lisinopril absorption is not affected by the presence of food.</p><p><strong>Distribution</strong><br />Lisinopril does not appear to be bound to serum proteins other than to circulating angiotensin-converting enzyme (ACE). Studies in rats indicate that lisinopril crosses the blood-brain barrier poorly.<br /><strong>Elimination</strong><br />Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine. On multiple dosing, lisinopril has an effective half-life of accumulation of 12.6 hours. The clearance of lisinopril in healthy subjects is approximately 50 ml/min. Declining serum concentrations exhibit a prolonged terminal phase, which does not contribute to drug accumulation. This terminal phase probably represents saturable binding to ACE and is not proportional to dose.<br /><strong>Hepatic impairment</strong><br />Impairment of hepatic function in cirrhotic patients resulted in a decrease in lisinopril absorption (about 30% as determined by urinary recovery), but an increase in exposure (approximately 50%) compared to healthy subjects due to decreased clearance.<br /><strong>Renal impairment</strong><br />Impaired renal function decreases elimination of lisinopril, which is excreted via the kidneys, but this decrease becomes clinically important only when the glomerular filtration rate is below 30 ml/min. In mild to moderate renal impairment (creatinine clearance 30-80 ml/min), mean AUC was increased by 13% only, while a 4.5- fold increase in mean AUC was observed in severe renal impairment (creatinine clearance 5-30 ml/min).<br />Lisinopril can be removed by dialysis. During 4 hours of haemodialysis, plasma lisinopril concentrations decreased on average by 60%, with a dialysis clearance between 40 and 55 ml/min.<br /><strong>Heart failure</strong><br />Patients with heart failure have a greater exposure of lisinopril when compared to healthy subjects (an increase in AUC on average of 125%), but based on the urinary recovery of lisinopril, there is reduced absorption of approximately 16% compared to healthy subjects.<br /><strong>Paediatric population</strong><br />The pharmacokinetic profile of lisinopril was studied in 29 paediatric hypertensive patients, aged between 6 and 16 years, with a GFR above 30 ml/min/1.73m2. After doses of 0.1 to 0.2 mg/kg, steady state peak plasma concentrations of lisinopril occurred within 6 hours, and the extent of absorption based on urinary recovery was about 28%. These values are similar to those obtained previously in adults.<br />AUC and Cmax values in children in this study were consistent with those observed in adults.</p><p><strong>Older people</strong><br />Older patients have higher blood levels and higher values for the area under the plasma concentration-time curve (increased approximately 60%) compared with younger subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. Angiotensin-converting enzyme inhibitors, as a class, have been shown to induce adverse effects on the late foetal development, resulting in foetal death and congenital effects, in particular affecting the skull. Foetotoxicity, intrauterine growth retardation and patent ductus arteriosus have also been reported. These developmental anomalies are thought to be partly due to a direct action of ACE inhibitors on the foetal renin-angiotensin system and partly due to ischaemia resulting from maternal hypotension and decreases in foetal-placental blood flow and oxygen/nutrients delivery to the foetus.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol<br />Calcium Hydrogen Phosphate dihydrate<br />Red Iron Oxide, in all strengths except the 2.5 mg (E172)<br />Maize Starch<br />Pregelatinised Starch<br />Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5, 10 and 20 mg tablets: Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 mg Tablets:&nbsp;Aluminium/PVC-PVDC, Aluminium/PVC or Aluminium/Aluminium foil blister calendar packs of 28 tablets.</p><p>10 mg Tablets: Aluminium/PVC-PVDC or Aluminium/PVC foil blister calendar packs of28 tablets.</p><p>20 mg Tablets: Aluminium/PVC-PVDC, Aluminium/PVC or Aluminium/Aluminium foil blister calendar packs of 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Naghi Brothers Company
P.O. Box 273, Jeddah 21411, A Malek RD. In front of Saudi oger, Jeddah, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>